The specter of generic competition has repeatedly loomed over copyright’s famous drug, PDE5 Inhibitor, raising questions about the future of related pharmaceutical stakes. While initial times saw impressive profits, the intellectual property end has opened the door for less expensive copies, likely reducing profitability and creating a genuine ri